News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This could be a Plus for CVSI Pro CBD in the present and future.
https://www.oann.com/newsroom/house-reps-introduce-bipartisan-legislation-to-ban-toxic-chemicals-from-cosmetics-and-personal-care-products/
Nice.
Best Balm 2024 +PlusCBD Full Spectrum CBD Balm, Extra Strength Formula
daily topical 100 MG CBD BALM FULL SPECTRUM
https://www.medicalnewstoday.com/articles/best-cbd-for-pain-management
sleuth100 thanks for that DD.
daily balance 10 MG CBD GUMMIES
https://www.medicalnewstoday.com/articles/cbd-gummies-for-anxiety
Agreed!
g247 Thank You for your valuable knowledge.
Charlotte's Web is a joke!!!!!! Their balance sheet does not reflect their untruthful statement!!!!!! "Improved loyalty programs and promotions introduced during the first quarter have increased new subscriber growth by approximately 25% quarter over quarter, with retention rates above 90%."
WISE 🐺 Wolf-man jack. I will continue to buy currently till .06.
A Plus for plant based products.
https://www.tampabay.com/news/florida-politics/2024/02/03/desantis-fake-meat-cultivated-lab-grown-cattle-industry/
Dive into the world of CBN with our Reserve Sleep products, backed by the comprehensive review.
https://www.pluscbdoil.com/cbd-products/cbd-gummies/reserve-collection-sleep-gummies.html
https://www.sciencedirect.com/science/article/pii/S0926669024003364
The June 4 meeting of the National Center for Complementary and Integrative Health (NCCIH) will convene dozens of NIH-funded researchers studying the pain-relieving properties of compounds in cannabis, and it will also feature a talk by officials at the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) and National Institute on Drug Abuse (NIDA) on cannabinoid research.
The event marks the final meeting of a group of investigators “who have been conducting NCCIH-supported projects on the mechanisms underlying the analgesic properties of minor cannabinoids and terpenes,” according to a blog from Inna Belfer, an NCCIH Deputy Branch Chief.
https://www.marijuanamoment.net/dea-fda-and-other-agencies-to-discuss-marijuanas-potential-to-treat-pain-at-upcoming-federal-research-meeting/
It was nice to jump in and get the buys going. Who bought 400,000 shares at $5.00 close to the closing and the 100,000 ?
“ Back in January, Tilray CEO Simon Irwin told the Wall Street Journal that Tilray would seek and be able to enter the U.S. "pretty quickly" upon rescheduling, either organically entering the U.S. or by acquiring another cannabis company. And while Cronos only sells cannabis in Canada, Germany, and Israel today, it's also 45% owned by cigarette giant Altria. While Cronos actually exited the U.S. CBD business last year and Altria has considered selling Cronos, one has to think Altria may have plans to attempt a U.S. entry for this subsidiary in light of rescheduling.”
https://finance.yahoo.com/news/why-cannabis-companies-tilray-canopy-201500541.html
https://mjbizdaily.com/cronos-pulls-plug-on-us-hemp-and-cbd-operations/
“ So the fact that CBD remains tied to marijuana in the DEA’s mind might turn out not to be a problem if pot as a whole ends up legal. In the meantime, there will be other products to feed DEA drug scheduling debates. Have you heard about the controversy over scheduling kratom? But therein hangs another tale.”
https://www.cbdmd.com/blogs/posts/is-cbd-oil-legal-a-look-at-dea-drug-scheduling
US drug control agency will move to reclassify marijuana in a historic shift
The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, The Associated Press has learned, a historic shift to generations of American drug policy that could have wide ripple-effects across the country.
The DEA’s proposal, which still must be reviewed by the White House Office of Management and Budget, would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than some of the nation’s most dangerous drugs. However, it would not legalize marijuana outright for recreational use.
The agency’s move, confirmed to the AP on Tuesday by five people familiar with the matter who spoke on the condition of anonymity to discuss the sensitive regulatory review, clears the last significant regulatory hurdle before the agency’s biggest policy change in over 50 years can take effect.
Once OMB signs off, the DEA will take public comment on the plan to move marijuana from its current classification as a Schedule I drug, alongside heroin and LSD. It moves pot to Schedule III, alongside ketamine and some anabolic steroids, following a recommendation from the federal Health and Human Services Department. After the public-comment period the agency would publish the final rule.
Read more: https://apnews.com/article/marijuana-biden-dea-criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8
The CVSI Outstanding increased by 693,615 Shares. MJ news by AP just now so I bought 80,800 shares of CVSI @ .03945 My Tilray’s up 26 percent on the news
|
Followers
|
568
|
Posters
|
|
|
Posts (Today)
|
1
|
Posts (Total)
|
83457
|
|
Created
|
02/27/13
|
Type
|
Free
|
| Moderators GE_Jim Zorax ap17 Wolf-man jack Thomas@yahoo | |||
AI
